Abivax (ABVX) Change in Accured Expenses (2024 - 2026)

Abivax (ABVX) posted quarterly Change in Accured Expenses of $7.7 million for Q1 2026, up 553.85% year-over-year from $1.2 million in Q1 2025, and up 38.47% quarter-over-quarter from $5.5 million in Q3 2025.

Abivax (ABVX) Change in Accured Expenses (2024 - 2026) Analysis & Trends

Abivax's Change in Accured Expenses history runs 3 years deep, the most recent figure standing at $7.7 million for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 222.50 Mn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 492.70 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - 55.78 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 212.44 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 61.62 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 68.82 Mn
10 Abivax 9.39 Bn 9.39 Bn - 7.68 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 7.68 Mn
Mar 31, 2026 7.68 Mn
Sep 30, 2025 5.54 Mn
Sep 30, 2025 5.54 Mn
Jun 30, 2025 332,796.15
Jun 30, 2025 332,796.15
Mar 31, 2025 -1.69 Mn
Mar 31, 2025 -1.69 Mn
Sep 30, 2024 -876,379.16
Sep 30, 2024 -876,379.16
Jun 30, 2024 861,510.06
Jun 30, 2024 861,510.06
Mar 31, 2024 -625,744.38
Mar 31, 2024 -625,744.38